FIELD: oncology.
SUBSTANCE: extended treatment regimen for HER-2/neu overexpressing/amplifying cancer including a course of treatment with neratinib in patients with HER-2/neu overexpressing/amplifying cancer after completion of surgical treatment and adjuvant therapy is described. The neratinib regimen may be extended for periods ranging from twelve months to five years.
EFFECT: proposed scheme provides a reduction in the risk of recurrence of the disease.
10 cl
| Title | Year | Author | Number |
|---|---|---|---|
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2009 |
|
RU2492860C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2013 |
|
RU2670974C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
| COMBINATION THERAPY WITH SEMAFORIN 4D (SEMA4D) BLOCKING AND DC1 THERAPY | 2020 |
|
RU2801828C2 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
